Baird stays Outperform on Mereo BipPharma Group (MREO) as market eyes regulatory path for setrusumab

March 24, 2026 9:36 AM

Baird analyst Jack Allen reiterated an Outperform rating and $1.00 price target on Mereo BipPharma Group (NASDAQ: MREO)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found